Indunil Karunarathna: A Comprehensive New Guide to Haemolytic Uremic Syndrome
Indunil Karunarathna, Founder of Uva Clinical Research Lab (UCRL), shared a post on LinkedIn:
“Haemolytic Uremic Syndrome: A Clinician’s Guide to Pathophysiological Subtypes, Diagnostic Differentiation, and Targeted Therapy (Dr Indunil Karunarathna Uva Clinical Research Lab 2026, Uva Clinical Anaesthesia and Intensive Care ISSN 2827-7198, 2026)
Haemolytic uremic syndrome (HUS) is a potentially catastrophic thrombotic microangiopathy defined clinically by the triad of microangiopathic hemolytic anemia, profound thrombocytopenia, and acute kidney injury.
Beneath this unified clinical presentation lies a spectrum of distinct etiologies, each with unique pathophysiological drivers, natural histories, and therapeutic implications.
Typical HUS, most often triggered by Shiga toxin–producing Escherichia coli (STEC), follows a diarrheal prodrome and generally responds to aggressive supportive care, including volume resuscitation and blood product support as needed.
In contrast, atypical HUS (aHUS) arises from uncontrolled alternative complement pathway activationtypically due to genetic mutations in regulatory proteins such as Factor H, Factor I, or membrane cofactor protein, or to acquired autoantibodiesand carries a high risk of progressive end-stage renal disease and mortality if not treated promptly with terminal complement inhibitors such as eculizumab or ravulizumab.
Secondary HUS encompasses cases driven by underlying conditions, including Streptococcus pneumoniae infection, autoimmune disease, malignancy, certain medications, or pregnancy, and requires treatment of the primary trigger often supplemented by complement blockade.
Differentiating among these subtypes is not an academic nicety but a clinical necessity, as management strategies differ fundamentally:
antibiotics and antimotility agents are avoided in STEC-HUS but may be indicated in other contexts, whereas complement inhibitors are life-saving in aHUS yet play no role in typical disease.
This review provides a conceptually grounded, clinically actionable framework for recognizing, evaluating, and managing HUS across the age spectrum, with emphasis on the pathophysiological rationale guiding each decision and the interprofessional collaboration essential for optimal outcomes.”

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines